Cogent Biosciences, Inc. (COGT) Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference Transcript

Core Viewpoint - Cogent Biosciences is conducting a webcast to discuss recent updates regarding their product bezuclastinib and related regulatory submissions [2][3]. Group 1: Company Updates - The company has announced updates related to their SM (specific product or initiative) over the weekend and this morning [2]. - The press releases regarding these updates are available on the company's website under the Investors and Media section [2]. Group 2: Leadership Remarks - Andrew Robbins, the President and CEO of Cogent Biosciences, is set to provide insights during the call [4].